Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23457371 | 1.00 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL23457377 | 0.97 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL23479750 | 0.97 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL13210176 | 0.88 | POLB (0.66) | ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL8986150 | 0.88 | POLB (0.66) | ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL13533671 | 0.86 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL4609230 | 0.84 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL26356582 | 0.82 | IKBKB (0.44) | POLB | |
| SCHEMBL23457397 | 0.82 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL23457426 | 0.82 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773127-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210171563-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171563-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, MPO | ALDH1A1 847/4885SMN1; SMN2 3669/4885POLB 905/4885 |
| US-11773127-B2 | Compounds and methods for treating bacterial infections | MMP8, ELANE, MPO | ALDH1A1 847/4885SMN1; SMN2 3669/4885POLB 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.